Search Images Maps Play YouTube News Gmail Drive More »
Advanced Patent Search | Web History | Sign in

Patents

The present invention relates generally to the fields of immunology and molecular biology, and particularly to a thymus-derived factor which stimulates, enhances or regulates cell-mediated immune responsiveness. In one embodiment, the factor is a substantially homogeneous immune potentiator which stimulates mature T lymphocytes and thus enhances the response of animals, especially mammalian organisms, to infectious agents and to malignancies.

Inventor: Terry R. Beardsley
Current U.S. Classification: 514/3.7; 514/3.8; 514/7.6; 514/21.2; 530/395; 530/397; 530/399
International Classification: A61K 3816

View patent at USPTO
Search USPTO Assignment Database

Citations

Cited PatentFiling dateIssue dateOriginal AssigneeTitle
US4120951May 9, 1977Oct 17, 1978Sloan-Kettering Institute for Cancer ResearchPolypeptide hormones of the thymus
US4571336Jan 25, 1985Feb 18, 1986Endorphin, Inc.Immune stimulation
US4716148Nov 18, 1986Dec 29, 1987Hoffman-La Roche Inc.Prothymosin alpha
US4720482Jun 5, 1986Jan 19, 1988Dana Farber Cancer InstitutePharmaceutical compositions containing one or more lymphocyte growth factors
US4722998Jun 5, 1986Feb 2, 1988Dana Farber Cancer InstituteMethod of producing lymphocyte growth factors
US4814434Nov 15, 1984Mar 21, 1989Ventres Laboratories, Inc.Inducer of T-suppressor cells
US4904643Jun 11, 1987Feb 27, 1990Ellem Industria Farmaceutica, s.r.l.Thymus derivative active after oral administration, methods of preparation and pharmaceutical compositions
US4965195Oct 7, 1988Oct 23, 1990Immunex Corp.Interleukin-7

Referenced by

Citing PatentFiling dateIssue dateOriginal AssigneeTitle
US7196060Sep 10, 2004Mar 27, 2007S-Cell Biosciences, Inc.Method to enhance hematopoiesis
US7776818Sep 29, 2006Aug 17, 2010S-Cell Biosciences, Inc.Methods to treat T-cell disorders using TISF
US8236323Feb 13, 2008Aug 7, 2012S-Cell Biosciences, Inc.Method to treat inflammation

Claims

1. An isolated thymus-derived cationic protein factor TISF expressed by a cloned type II thymic epithelial cell line of human, bovine, canine or feline origin, having a molecular weight of about 50,000 Daltons on a polyacrylamide gel, an isoelectric point of about 6.5, and capable of inducing or enhancing cell-mediated immune responsiveness of mature T-cells and stimulating IL-2 production in a mammal.

2. The factor of claim 1, of feline origin.

3. The factor of claim 1, of canine origin.

4. The factor of claim 1, of bovine origin.

5. The factor of claim 1, of human origin.

6. The factor according to claim 1, wherein said factor has the ability to enhance the response of a mammal to infection agents.

7. A composition comprising an effective, immune-responsiveness-enhancing amount of thymus-derived factor according to claim 1 incorporated in a pharmaceutically acceptable carrier or excipient.

8. A composition according to claim 7, in a form suitable for parenteral administration.

9. A composition according to claim 7, in a form suitable for intraperitoneal administration.

10. A composition according to claim 7, in a form suitable for topical administration.

11. A composition according to claim 7, in a form suitable for oral administration.

12. A method for enhancing immune responsiveness of a mammal against a virus selected from the group consisting of Feline Immunodeficiency Virus, rabies virus, influenza virus, and distemper virus, comprising administering to said, mammal an effective immune response-enhancing amount of the factor of claim 1.

13. A method for enhancing immune responsiveness of a mammal against a virus selected from the group consisting of Feline Immunodeficiency Virus, rabies virus, influenza virus, and distemper virus, comprising administering to said mammal an effective immune response-enhancing amount of the factor of claim 7.

14. A method according to claim 12, wherein said virus is Feline Immunodeficiency Virus.

15. A method according to claim 12, wherein said virus is rabies virus.

16. A method according to claim 12, wherein said virus is distemper virus.

17. The method of claim 12, wherein said mammal is a feline.

18. The method of claim 12, wherein said mammal is a canine.

19. The method of claim 12, wherein said mammal is a human.

20. The method of claim 18, wherein said factor is administered parenterally.

21. The method of claim 12, wherein said factor is administered intraperitoneally.

22. The method of claim 12, wherein said factor is administered after being incorporated within liposomes.

23. The method of claim 12, wherein said factor is administered topically.

24. The method of claim 12, wherein said factor is administered orally.

Drawings